The purpose of this study is to evaluate the safety, tolerability and overall response rate
of carfilzomib in combination with dexamethasone for the treatment of multiple myeloma in
We will connect you to the doctor responsible for this trial and help you get more information.
Locations near you
Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Full eligibility criteria for NCT03029234
Ages eligible for Study
18 Years and older
Genders eligible for Study
Accepts Healthy Volunteers
Subjects must have measurable disease, defined as one or more of the following:
Serum M-protein ≥ 1 g/dL
Urine M-protein ≥ 200 mg/24 hours
In subjects without measurable serum or urine M-protein, SFLC > 100 mg/L (involved light chain) and an abnormal κ/λ ratio
Subjects must have been responsive (ie, achieved a minimal response [MR] or better) to at least one of their prior treatment regimens
Refractory to the most recently received therapy. Refractory disease defined as ≤ 25% response to, or progressing during therapy or within 60 days after completion of therapy
Subjects must have received ≥ 2 prior regimens. Induction therapy and stem cell transplant (± maintenance) will be considered as 1 regimen
Subjects must have received prior treatment with bortezomib and an IMiD
Subjects must have received an alkylating agent or anthracycline alone or in combination with other myeloma treatments (this may include high dose melphalan as part of the conditioning regimen prior to a stem cell transplant)
Males and females ≥ 18 years of age
Life expectancy of more than 3 months
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2
Adequate hepatic function, with bilirubin < 2.0 times the upper limit of normal (ULN), and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3.0 times the ULN
Subjects should not have received platelet transfusions for at least 1 week prior to obtaining the screening platelet count
Screening ANC should be independent of granulocyte colony stimulating factor
(G-CSF) or granulocyte macrophage colony stimulating factor (GM-CSF) support for
≥ 1 week and pegylated G-CSF for ≥ 2 weeks
Use of erythropoietic stimulating factors and red blood cell (RBC) transfusions per institutional guidelines is allowed; however, most recent RBC transfusion may not have been done within 7 days prior to obtaining screening hemoglobin
Calculated or measured creatinine clearance (CrCl) of ≥ 30 mL/min. Calculated CrCl should be performed by using a widely accepted equation (eg, the Cockcroft and Gault equation): ([140 - Age] × Mass [kg] / [72 × Creatinine mg/dL]). Multiply the result by 0.85 if the subject is female.
Left ventricular ejection fraction (LVEF) ≥ 40%; 2-dimensional transthoracic echocardiogram (ECHO) is the preferred method of evaluation; multiple gated acquisition scan (MUGA) is acceptable if ECHO is not available
Written informed consent in accordance with federal, local, and institutional guidelines
Female subjects of child-bearing potential (FCBP) must have a negative serum pregnancy test within 21 days prior to enrollment and agree to use an effective method of contraception during and for 30 days following last dose of carfilzomib. This protocol defines a FCBP as a sexually mature woman who: 1) has not undergone a hysterectomy, bilateral oophorectomy, or bilateral salpingectomy, or 2) has not been naturally postmenopausal for at least 24 consecutive months (ie, has had menses at any time in the preceding 24 consecutive months)
Male subjects must use an effective barrier method of contraception during the study and for 3 months following the last dose of carfilzomib if sexually active with a FCBP. Male subjects must not donate sperm during treatment and for an additional 90 days after last dose of carfilzomib. Male subjects with pregnant partners must practice sexual abstinence or use a condom during vaginal sex
Waldenström's macroglobulinemia or immunoglobulin M (IgM) multiple myeloma
Subjects who failed to achieve at least a confirmed MR on any of their prior regimens
Subjects with non-secretory multiple myeloma, defined as < 1 g/dL M-protein in serum and < 200 mg/24 hour M- protein in urine and SFLC ≤ 100 mg/L (involved light chain)
Glucocorticoid therapy (prednisone > 10 mg/day or equivalent) within 3 weeks prior to Cycle 1 Day 1
POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)
Plasma cell leukemia (> 2.0 × 109/L circulating plasma cells by standard differential)
Chemotherapy with approved or investigative anticancer therapeutics including steroid therapy within the 3 weeks prior to Cycle 1 Day 1
Radiation therapy or immunotherapy in the 4 weeks prior to Cycle 1 Day 1; localized radiation therapy within 1 week prior to Cycle 1 Day 1
Participation in an investigational therapeutic study within 3 weeks or within 5 drug half-lives (T½) prior to Cycle 1 Day 1, whichever time is greater
Prior treatment with carfilzomib
Major surgery within 3 weeks before Cycle 1 Day 1
Congestive heart failure ([CHF] New York Heart Association Class III to IV), symptomatic ischemia, conduction abnormalities uncontrolled by conventional intervention, or myocardial infarction within 6 months prior to Cycle 1 Day 1
Uncontrolled hypertension (a sustained systolic blood pressure > 140 mmHg and/or diastolic BP > 90 mmHg)
Acute active infection requiring systemic antibiotics, antivirals, or antifungals within 2 weeks prior to Cycle 1 Day 1
Known HIV seropositive, hepatitis C infection, and/or hepatitis B (except for patients with hepatitis B surface antigen or core antibody receiving and responding to antiviral therapy directed at hepatitis B: these patients are allowed)
Non-hematologic malignancy within the past 3 years except:
Adequately treated basal cell or squamous cell skin cancer,
Carcinoma in situ of the cervix, or
Prostate cancer < Gleason Score 6 with stable prostate-specific antigen
Subjects with treatment-related myelodysplastic syndrome
Significant neuropathy (Grade 3, 4, or Grade 2 with pain) at the time of baseline evaluation
Subjects in whom the required program of PO or IV fluid hydration is contraindicated, eg, due to pre-existing pulmonary, cardiac, or renal impairment
Subjects with known or suspected amyloidosis
Subjects with pleural effusions requiring thoracentesis
Subjects with ascites requiring paracentesis
Any clinically significant medical disease or condition, that in the investigator's opinion, may interfere with protocol adherence or a subject's ability to give informed consent
Female subjects who are pregnant or lactating, or planning to become pregnant during treatment and for an additional 30 days after discontinuing carfilzomib.
Serious psychiatric or medical conditions that could interfere with treatment
All locations for NCT03029234
Beijing, Beijing, China, 100020
Beijing, Beijing, China, 100191
Fuzhou, Fujian, China, 350001
Guangzhou, Guangdong, China, 510060
Guangzhou, Guangdong, China, 510180
Zhengzhou, Henan, China, 450008
Wuhan, Hubei, China, 430014
Suzhou, Jiangsu, China, 215004
Changchun, Jilin, China, 130021
Shenyang, Liaoning, China, 110001
Shanghai, Shanghai, China, 200032
Chengdu, Sichuan, China, 610041
Tianjin, Tianjin, China, 300020
Tianjin, Tianjin, China, 300052
Hangzhou, Zhejiang, China, 310003
Beijing, China, 100730
Shanghai, China, 200003
View full eligibility
Tris trial is registered with FDA with number: NCT03029234. The sponsor of the trial is Amgen and it is looking for 126 volunteers for the current phase.
Official trial title: An Open-label, Single-arm, Phase 3 Study of Carfilzomib in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma in China
1What's a trial
4Get in touch
What's a trial
Not sure you're well informed about clinical trials? Learn more about their benefits, risks and other important details.
Enter your details like condition, age, gender and other preferences and we will show you a list of all relevant clinical trials.
Review the summary of the selected clinical trial and all the locations near you in order to see if it's of interest to you.
Get in touch
You've found an interesting trial? We'll need a bit more information about you so we can connect you to the doctor in charge.
Thank you for applying!
We'll contact you soon with more information.
Consult your doctor?
Some people want to consult their doctor before considering participation in a clinical trial. This is absolutely normal as your doctor should know your medical history and should be able to advise you. If you want you can easily share the information for this trial with your doctor by clicking on the button below.